

|              |   |
|--------------|---|
| <b>DATE:</b> | 16 October 2023   |
| <b>TO:</b>   | Physicians and Nursing Staff, All Zones                 |
| <b>FROM:</b> | APL Transfusion Medicine                                |
| <b>RE:</b>   | <b>Updates to Transfusion Medicine Client Resources</b> |

---

**PLEASE POST OR DISTRIBUTE AS WIDELY AS APPROPRIATE**

---

## Key Message

- New and revised Transfusion Medicine resources are available on [www.ahs.ca/labtransfusion](http://www.ahs.ca/labtransfusion).
- These resources provide information to support safe and appropriate transfusion practice in alignment with the [AHS Transfusion of Blood Components and Blood Products Policy](#)

## Background

- Blood Component & Product Information / Monographs provide specific information required for obtaining, preparing, and transfusing blood components and products available in Alberta hospitals.

## Action Required

- Review the most current version of the applicable Blood Component or Product Information / Monograph before transfusion.
- Review the new resources for changes that impact your zones.

| Document  | Rev # | Rev Date  | Notes  |
|---|-------|-----------|--|
| <b>New Resources</b>  |       |           |  |
| <a href="http://albertahealthservices.ca">Massive Hemorrhage Protocol (albertahealthservices.ca)</a>  | 1.00  | Sept 2023 | <p>New Provincial Massive Hemorrhage Protocol and resources</p> <p><b>Effective:</b></p> <p><b>October 25, 2023 - Edmonton Zone, Calgary Zone, and the Grand Prairie</b></p> <p><b>January 15, 2024: Northern Lights Regional Hospital, Red Deer Regional Hospital, and South zone sites</b></p> |
| <a href="http://albertahealthservices.ca">Massive Hemorrhage Protocol appendix A greater than or equal to 50kg (albertahealthservices.ca)</a> | 1.00  | Sept 2023 |  |
| <a href="http://albertahealthservices.ca">Massive Hemorrhage Protocol appendix B less than 50kg (albertahealthservices.ca)</a>                | 1.00  | Sept 2023 |  |
| <a href="http://albertahealthservices.ca">Managing a Hemorrhaging Patient Protocol-Rural and Suburban Sites (albertahealthservices.ca)</a>    | 1.00  | Sept 2023 |  |



| Document  | Rev # | Rev Date  | Notes   |
|---|-------|-----------|---|
| <b>Revised Blood Component Monographs</b>   |       |           |   |
| <a href="#">TM40-01.02.020<br/>RiaSTAP Product Info</a>   | 2.31  | 31Aug2023 | Minor revision. Added statement re administration of blood components and products is a restricted activity. Removed references to cryoprecipitate. Added dosing chart with updated indications. Sorted order of administration options (most frequent to least).   |
| <a href="#">TM40-01.02.021<br/>RiaSTAP Reconstitution</a>   | 2.01  | 31Aug2023 | Minor revision. Updated link to RiaSTAP Product Info.   |
| <a href="#">Fibryga Fibrinogen Concentrate<br/>(albertahealthservices.ca)</a>   | 1.01  | 31Aug2023 | Minor revision. Updated to APL template. Changed “intermittent” infusion to “IV” infusion. Added statement re administration of blood components and products is a restricted activity. Removed references to cryoprecipitate. Added dosing chart with updated indications. Removed reconstitution supplies section. Updated Administration section and sorted order of administration options (most frequent to least). Updated link to transfusion reactions chart. Added the Don’t Misuse My Blood Project clinical decision support tools |
| <a href="#">Fibryga reconstitution instructions<br/>(albertahealthservices.ca)</a>  | 1.01  | 31Aug2023 | Minor revision. Changed document number from PTMGNR00068 to TM40-01.02.003. Updated to APL template. Updated Supplies Required and Instructions sections as per manufacturer’s product monograph.   |
| <b>Revised Information</b>  |       |           |   |
| <a href="#">TM40-05.009<br/>Transfusion of Blood Components and Blood Products Policy FAQ<br/>(albertahealthservices.ca)</a>  | 2.00  | 23Aug2023 | Addition of question-and-answer number 29, for clarification of the infusion rate in patients less than 25kg.   |
| <b>Obsolete / Archived Documents</b>  |       |           |   |
| COVID-19 Pandemic Transfusion Guidelines for Specific Patient Populations Malignant Hematology Patients - Prophylactic Transfusion Guidelines<br><br>Cell Therapy Transplant Canada COVID-19 Position Statement | N/A   | N/A       | Removed COVID-19 resources, no longer required.   |
| COVID-19 Convalescent Plasma and IVIG<br><br>National Clinical Trial: COVID-19 Convalescent Plasma CBS Donor Registry<br><br>Convalescent Plasma and Intravenous Immune Globulin                                | N/A   | N/A       | Removed COVID-19 resources, no longer required.   |



| Document   | Rev # | Rev Date | Notes |
|--|-------|----------|-------|
| (IVIg) for Treatment of COVID-19 in Canada – Fact Sheet  |       |          |       |
| Convalescent Plasma and Intravenous Immune Globulin (IVIg) for Treatment of COVID-19 Infection – NEBMC Statement |       |          |       |

**Questions/Concerns**

- APL Transfusion Safety Team - [Transfusion.SafetyTeam@aplabs.ca](mailto:Transfusion.SafetyTeam@aplabs.ca)

**Approved by**

- Dr. Susan Nahirniak, Medical Director, APL Transfusion and Transplantation Medicine Program

*Effective September 1, 2023, APL has become the sole provider of all public lab services in Alberta. As a result, community lab services formally provided by DynaLIFE Medical Labs will become the responsibility of Alberta Precision Labs (APL). This change impacts all zones.*